The longitudinal nature of the data that the PHARMO Institute has access to, enables the follow-up more than 10 million persons of a well-defined population in the Netherlands for an average of twelve years. Currently, over 7 million active persons out of 17 million inhabitants of the Netherlands are captured. Data collection period, catchment area and overlap between data sources differ. Therefore, the final cohort size for any study will depend on the data sources included. As data sources are linked on an annual basis, the average lag time of the data is one year. All electronic patient records include information on age, sex, socioeconomic status and mortality. Other available information depends on the data source.
We use data of
The PHARMO Institute has access to study-specific datasets derived from a network of electronic healthcare databases encompassing anonymous data from different primary and secondary healthcare settings in the Netherlands. These different data sources are linked on a patient level through validated algorithms. To ensure the privacy of the data, the collection, processing, linkage and anonymisation of the data is performed by STIZON. STIZON is an independent, ISO/IEC 27001 certified foundation, which acts as a Trusted Third Party (TTP) between the data sources and the PHARMO Institute.